

Albendazole cuts enteric parasite prevalence in refugees

April 19 2012



(HealthDay) -- The administration of a single 600-mg dose of albendazole to United States-bound refugees prior to departure from Africa and Southeast Asia reduces the prevalence of intestinal nematodes, according to a study published in the April 19 issue of the *New England Journal of Medicine*.

Stephen J. Swanson, M.D., of the Epidemic Intelligence Service in Atlanta, and colleagues conducted a <u>retrospective cohort study</u> of 26,956 refugees from Africa and Southeast Asia. The refugees underwent stool specimen screening for intestinal parasites. The prevalence of intestinal nematodes, schistosoma species, giardia, and entamoeba was compared among refugees who migrated before and after the U.S. Centers for Disease Control and Prevention's recommendation of presumptive



predeparture albendazole treatment.

"These data provide evidence that implementation of an overseas protocol for presumptive single-dose albendazole therapy in refugees was associated with substantial decreases in infections with multiple intestinal parasites," the authors write. "Targeting these diseases among refugees has yielded reductions in parasite burdens and may improve the health of this population."

More information: <u>Full Text (subscription or payment may be required)</u>

Copyright © 2012 HealthDay. All rights reserved.

Citation: Albendazole cuts enteric parasite prevalence in refugees (2012, April 19) retrieved 23 June 2024 from

https://medicalxpress.com/news/2012-04-albendazole-parasite-prevalence-refugees.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.